Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar i disorder: Analysis of two large randomized, placebo-controlled trials

Depression and Anxiety

Volumn 30, Issue 11, 2013, Pages 1089-1098

  Suppes, Trisha ^a,b   Vieta, Eduard ^c   Gustafsson, Urban ^d   Ekholm, Birgit ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d ASTRAZENECA R AND D   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

bipolar depression; combination drug therapy; efficacy; mania; safety

Indexed keywords

LITHIUM; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; BIPOLAR I DISORDER; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LITHIUM BLOOD LEVEL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

BIPOLAR DEPRESSION; COMBINATION DRUG THERAPY; EFFICACY; MANIA; SAFETY;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84887254421     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22136     Document Type: Article

References (32)

1. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870-886. (Pubitemid 41032829)
2. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255.
3. Sajatovic M, Valenstein M, Blow F, et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58: 855-863. (Pubitemid 46985180)
4. Licht RW, Nielsen JN, Gram LF, et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-493.
5. Goodwin GM,. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388.
6. Goldberg JF, Brooks JO, III, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009; 70: 155-162.
7. Keck PE, Jr,. Long-term management strategies to achieve optimal function in patients with bipolar disorder. J Clin Psychiatry 2006; 67 (Suppl 9): 19-24. (Pubitemid 44369651)
8. Ketter TA,. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008; 69 (Suppl 5): 9-15.
9. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129: 14-26.
10. Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011; 14: 1029-1049.
11. Derry S, Moore RA,. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7: 40-57.
12. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010; 13: 5-14.
13. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137.
14. Pae CU, Masand PS, Mandel FS, O'Gorman C,. Achieving and sustaining remission in bipolar I disorder with ziprasidone: a post hoc analysis of a 24-week, double-blind, placebo-controlled study. Clin Drug Investig 2012; 32: 747-754.
15. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345. (Pubitemid 38491170)
16. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488.
17. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA,. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435. (Pubitemid 9006756)
19. Montgomery SA, Asberg M,. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389. (Pubitemid 9136500)
20. Sheehan DV,. The Anxiety Disease. New York, NY: Charles Scribner & Sons; 1983.
21. Dupuy HJ,. The Psychological General Well-being (PGWB) Index. In:, Wenger NK, Mattson ME, Furberg CD, Elinson J, editors. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York, NY: Le Jacq Publishing Inc.; 1984: 170-183.
22. Simpson GM, Angus JW,. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
23. Barnes TR,. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676. (Pubitemid 19154942)
24. Guy W,. ECDEU Assessment Manual for Psychopharmacology. Revised ed. Washington, DC: US Department of Health, Education and Welfare; 1976.
25. Post RM, Altshuler LL, Frye MA, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010; 71: 1176-1186.
26. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400. (Pubitemid 36403000)
27. Grandjean EM, Aubry JM,. Lithium: updated human knowledge using an evidence-based approach: part I: clinical efficacy in bipolar disorder. CNS Drugs 2009; 23: 225-240.
28. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395.
29. Severus WE, Kleindienst N, Evoniuk G, et al. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study. J Affect Disord 2009; 115: 466-470.
30. Leber PD, Davis CS,. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998; 19: 178-187. (Pubitemid 28191972)
31. Newcomer JW, Haupt DW,. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480-491. (Pubitemid 44166336)
32. Seroquel [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.